Protara Therapeutics, Inc. — Director's Dealing 2017

Jan 26, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PROTEON THERAPEUTICS INC (PRTO)
CIK: 0001359931
Period of Report: 2017-01-24

Reporting Person: NOYES TIMOTHY P (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-01-24	Stock Option (Right to Buy)	$2.05	A	122838	Acquired	2027-01-23	Common Stock, $0.001 par value (122838)	Direct

Footnotes

F1: The options were granted on January 24, 2017 and the shares underlying this option vest 25% on the first anniversary of the grant date and the remaining shares vest in twelve equal quarterly installments.